Full Press Release Details
Corporate Presentation
Therapeutics www.galectintherapeutics.com
Forward Looking Statements
contains, in addition to historical information, statements that look forward in time or that express management s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial
performance, and use words such as may, estimate, could, expect and others. They are based on our current expectations and are subject to risks and uncertainties that could cause actual results to
differ materially from those described in the statements. These statements include our plans, expectations and goals regarding drugs in development, clinical trials and regulatory approval for any of our drugs or treatments, the anticipated timeline
for clinical trials and results, related market opportunities for our drugs, potential benefits of our drugs, efforts related to partnering opportunities with other companies, estimates regarding cash and spending, liquidity and funding requirements
for clinical trials, and estimates regarding those impacted by NASH, liver fibrosis and cirrhosis. The risks and uncertainties impacting these statements include that our plans, expectations and goals regarding drugs in development, clinical trials
and regulatory approval are subject to factors beyond our control. Our clinical trials may not begin or produce positive results in a timely fashion, if at all, and any necessary changes during the course of such trials could prove time consuming
and costly. We may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Upon receipt of regulatory approval for any drug or treatment, we may face competition with other drugs and treatments that
are currently approved or those that are currently in development, which could have an adverse impact on our ability to achieve revenues from the approved indication. Plans regarding development, approval and marketing of any of our drugs are
subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies.
Estimates regarding the potential benefits of our drugs and the potential market for any of our drugs may be inaccurate and, to the extent the estimates are correct, we may not be
successful in achieving revenues from any such drugs, as the successful marketing of any approved drugs will be subject to strong competition within the health care industry and patient and physician acceptance of our drugs as safe, affordable and
effective. Our ongoing discussions with other companies may not lead to partnering opportunities, and if we are unable to partner with other companies and/or raise additional capital, we will likely be unable to complete future stages of clinical
trials and ultimately produce revenue from our drugs in development. Funding from potential sources of capital, including the potential exercise of warrants, may not materialize. To date, we have incurred operating losses since our inception, and
our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our most recent Annual Report on Form 10-K
and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.
2014 Galectin Therapeutics NASDAQ:GALT
The Company and Key Team Members
Fibrosis Program our primary focus Cancer Immunotherapy Summary
2014 Galectin Therapeutics NASDAQ:GALT
Clinical stage biopharmaceutical
company targeting fibrotic diseases and cancer with novel compounds that inhibit galectin proteins (galectin-3)
Galectin proteins are important in the development and promotion of many inflammatory, fibrotic and neoplastic diseases
Currently in clinical trials in liver fibrosis and cancer
Liver fibrosis indication: NASH (Fatty Liver Disease) with advanced liver fibrosis Cancer immunotherapy indication:
2014 Galectin Therapeutics NASDAQ:GALT
Key Facts As of January 9, 2014
Trading Symbol Nasdaq: GALT
Corporate Headquarters Norcross, GA (suburb of Atlanta)
Stock Price; 52 Week Range $13.49 $1.99 $14.20
Shares Outstanding 20.7 million
Daily Volume (50 day average) 332,583 shares
Market Capitalization $279 million
Cash & Equivalents $32.3 million
Estimated Spending in 2014 $14.5 million
Fiscal Year Ends December 31
Accounting Firm McGladrey LLP
Galectin Therapeutics NASDAQ:GALT
Experienced Leadership Team
Peter G. Traber, MD President, CEO, CMO
Harold H. Shlevin, PhD
Regulatory Affairs and
Manager and general partner of 10x Fund, L.P., Co-Founder, Pro-Pharmaceuticals, CEO, Minerva Biotechnologies
Over 28 years experience in biomedicine and Pharmaceutical industries in research and development,
clinical medicine and business development.
GlaxoSmithKline (CMO), Un of Pennsylvania (CEO, Chief of GI,
Chairman of Medicine), Baylor College Medicine (CEO)
Over 32 years of senior experience in the development and
commercialization of pharmaceuticals and business development including mergers and acquisitions.
Pharmaceuticals (CEO), CIBA Vision Ophthalmics (nka Novartis Vision) (SVP & co-founder), Tikvah Therapeutics (Founder, CEO), Board of Directors, Cardiome Pharma Corp. (NASDAQ: CRME)
Over 24 years in accounting and finance with life science and technology companies with significant experience in
negotiating and closing financing transactions.
CFO Reach Health, CFO of Vystar Corporation, CFO Corautus
Over 30 years experience in biotechnology engineering and regulatory in pharmaceuticals and
Koor Biotechnologies, Charm Sciences Glycogenesis, HU Medical School (Jerusalem), Harvard
Over 24 years of experience working in the biotech and life sciences industries, regulatory affairs
Director Regulatory Affairs at Solvay Pharmaceuticals and Chelsea Therapeutics, Georgia
Institute of Technology.
2014 Galectin Therapeutics NASDAQ:GALT
The Company and Key Team Members
Fibrosis Program our key focus Cancer Immunotherapy Summary
2014 Galectin Therapeutics NASDAQ:GALT
Galectins Inhibitors
Galectin family (15 members)
are classified by structure and the number of carbohydrate binding domains (CRD).
Galectins bind via their CRD
to oligosaccharides containing terminal galactose residues on macromolecules such as glycoproteins.
through binding glycoproteins on cell surface and extracellular space to modulate cellular and immune system function.
Galectin-3 is widely expressed, but highest in immune cells (macrophages)
Under normal physiological situations, galectin-3 is expressed at low levels In areas of acute or chronic inflammation and fibrogenesis, the gal-3 expression is markedly increased. The
majority of cancers express high levels of galectin-3
Our proprietary drugs are complex carbohydrates with
galactose residues that bind galectin proteins (galectin-3 > galectin-1)
Galactomannan (GM) class: GM-CT-01
Galacto-rhamnogalaturonate (GR) class: GR-MD-02
Derivatives of GM and GR for subcutaneous administration Synthetic carbohydrates Small organic molecule galectin inhibitors
2014 Galectin Therapeutics NASDAQ:GALT
Intellectual Property
GM-CT Class (current NCE is
US Composition of matter patent issued 2011 (expires 2023)
Five US issued method of use patents in combination with cancer therapy for increased efficacy and reduced side effects
International Patents: 14 granted and 5 pending Method of use in liver fibrosis issued 2012 (expires 2026) Multiple method of use patents pending, but all uses covered by composition claims.
GR-MD Class (current NCE is GR-MD-02)
Composition of matter patent pending (priority 2011) Method of use in liver fibrosis patent issued (expires 2026) Method of use in NASH patent issued (expires 2031) Method of use for
Cancer Immunotherapy pending (priority 2011) Method of use in Diabetic nephropathy pending (priority 2011) Method of use in lung fibrosis pending (priority 2012)
Sole ownership of compounds in development
2014 Galectin Therapeutics NASDAQ:GALT
The Company and Key Team Members Galectins
Fibrosis Program our key focus
Cancer Immunotherapy Summary
2014 Galectin Therapeutics NASDAQ:GALT
Fundamental Science on Target is Strong: Galectin-3 is critically important in the development of organ fibrosis
Galectin-3 null mice (no galectin-3) are resistant to fibrosis due to toxin-induced liver toxicity
Red stain is collagen, the principal component of fibrotic tissue
Mice treated with liver toxin to induce fibrosis
Normal mice develop fibrosis
whereas those without gal-3 do not